Written Question·Department of Health and Social Care·UIN 119738

Donanemab and Lecanemab

Tabled: 10 March 2026
Answered: 19 March 2026
Named Day

Question

Freddie van Mierlo

Liberal DemocratHenley and Thame

To ask the Secretary of State for Health and Social Care, when he expects NICE to publish the outcomes of the appeals on its final draft guidance on donanemab and lecanemab.

Answer

Dr Zubir Ahmed
The appeals against the National Institute for Health and Care Excellence (NICE) recommendations on donanemab and lecanemab for the treatment of Alzheimer’s disease were heard by NICE’s independent appeal panel in January. The next steps of the appraisal ...

This is an extract from the Parliament API. Search the full answer on Parliament.uk (UIN 119738) →

Donanemab and Lecanemab — Written Question | TrustPolitics